TRANSFORMATIVE CELL PROCESSING CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Regenerative Medicine, iPS Stem Cell Mass Production Process Research and Development
The content above was translated by Ai
Founded Year
2022
Unified Business No.
90278081
Status
Active
Number of Employees
0
Total Paid-in
Capital
224,563,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
TRANSFORMATIVE CELL PROCESSING CO., LTD. is a spin-off company of National Yang Ming Chiao Tung University, established in August 2022. By combining Taiwan's strengths in regenerative medicine and semiconductor technology mass production, the company aims to utilize semiconductor technology to optimize manufacturing production lines and reduce costs, thereby providing high-quality iPS cells and related products, and making iPS cell manufacturing an affordable medical product for the general public. TRANSFORMATIVE CELL PROCESSING CO., LTD. also takes achieving "ONE HEALTH"—which promotes human and animal health and maintains and improves the ecological environment—as its strategic goal. Currently, TRANSFORMATIVE CELL PROCESSING CO., LTD. will leverage Japan's leading R&D achievements in iPS, coupled with the outstanding talent and cost control capabilities of Taiwan's technology industry, to add wings to iPS cell preparation technology, hoping to carry humanity to soar into a new horizon of regenerative medicine.
The content above was translated by Ai
